Tags

Type your tag names separated by a space and hit enter

Development of an inactivated vaccine candidate for SARS-CoV-2.
Science. 2020 07 03; 369(6499):77-81.Sci

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.

Links

PMC Free PDF

Authors+Show Affiliations

Gao Q
Sinovac Biotech Ltd., Beijing, China.
Bao L
Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
Mao H
Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Wang L
Sinovac Biotech Ltd., Beijing, China.
Xu K
Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China.
Yang M
CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Li Y
Sinovac Biotech Ltd., Beijing, China.
Zhu L
CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Wang N
CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Lv Z
CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Gao H
Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
Ge X
Sinovac Biotech Ltd., Beijing, China.
Kan B
National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China.
Hu Y
Sinovac Biotech Ltd., Beijing, China.
Liu J
Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
Cai F
Sinovac Biotech Ltd., Beijing, China.
Jiang D
Sinovac Biotech Ltd., Beijing, China.
Yin Y
Sinovac Biotech Ltd., Beijing, China.
Qin C
Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
Li J
Sinovac Biotech Ltd., Beijing, China.
Gong X
Sinovac Biotech Ltd., Beijing, China.
Lou X
Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Shi W
Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Wu D
Sinovac Biotech Ltd., Beijing, China.
Zhang H
Sinovac Biotech Ltd., Beijing, China.
Zhu L
Sinovac Biotech Ltd., Beijing, China.
Deng W
Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
Li Y
Sinovac Biotech Ltd., Beijing, China.
Lu J
National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
Li C
Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
Wang X
CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
Yin W
Sinovac Biotech Ltd., Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
Zhang Y
Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
Qin C
Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.

MeSH

AnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCOVID-19COVID-19 VaccinesChlorocebus aethiopsCoronavirus InfectionsDose-Response Relationship, ImmunologicFemaleImmunogenicity, VaccineImmunoglobulin GMacaca mulattaMaleMiceMice, Inbred BALB CPandemicsPilot ProjectsPneumonia, ViralRatsRats, WistarSARS-CoV-2Vaccines, InactivatedVero CellsViral LoadViral Vaccines

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32376603

Clinical Trial Links

Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)
Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations
Adverse Events Report of Inactivated COVID-19 Vaccine

Citation

Gao, Qiang, et al. "Development of an Inactivated Vaccine Candidate for SARS-CoV-2." Science (New York, N.Y.), vol. 369, no. 6499, 2020, pp. 77-81.
Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77-81.
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., ... Qin, C. (2020). Development of an inactivated vaccine candidate for SARS-CoV-2. Science (New York, N.Y.), 369(6499), 77-81. https://doi.org/10.1126/science.abc1932
Gao Q, et al. Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science. 2020 07 3;369(6499):77-81. PubMed PMID: 32376603.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of an inactivated vaccine candidate for SARS-CoV-2. AU - Gao,Qiang, AU - Bao,Linlin, AU - Mao,Haiyan, AU - Wang,Lin, AU - Xu,Kangwei, AU - Yang,Minnan, AU - Li,Yajing, AU - Zhu,Ling, AU - Wang,Nan, AU - Lv,Zhe, AU - Gao,Hong, AU - Ge,Xiaoqin, AU - Kan,Biao, AU - Hu,Yaling, AU - Liu,Jiangning, AU - Cai,Fang, AU - Jiang,Deyu, AU - Yin,Yanhui, AU - Qin,Chengfeng, AU - Li,Jing, AU - Gong,Xuejie, AU - Lou,Xiuyu, AU - Shi,Wen, AU - Wu,Dongdong, AU - Zhang,Hengming, AU - Zhu,Lang, AU - Deng,Wei, AU - Li,Yurong, AU - Lu,Jinxing, AU - Li,Changgui, AU - Wang,Xiangxi, AU - Yin,Weidong, AU - Zhang,Yanjun, AU - Qin,Chuan, Y1 - 2020/05/06/ PY - 2020/04/10/received PY - 2020/05/02/accepted PY - 2020/5/8/pubmed PY - 2020/7/16/medline PY - 2020/5/8/entrez SP - 77 EP - 81 JF - Science (New York, N.Y.) JO - Science VL - 369 IS - 6499 N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans. SN - 1095-9203 UR - https://www.unboundmedicine.com/medline/citation/32376603/Development_of_an_inactivated_vaccine_candidate_for_SARS_CoV_2_ DB - PRIME DP - Unbound Medicine ER -